Indian pharmaceutical companies are planning to supply drugs to Saudi Arabia in therapeutic segments like HIV/AIDS, TB, hypertension, infectious diseases, bacterial infections, and mental illness, among others.

These key therapeutic segments have been covered as part of the 300 life-saving drugs list shared with the Indian Drug Manufacturers Association (IDMA) by the Saudi Food and Drug Authority (SFDA), Kingdom of Saudi Arabia, for which the latter has invited the Indian Pharma companies to supply drugs based on the local requirement.

Click for more articles on Indian Pharma Companies

The list of drugs includes:

- Dexamethasone, which is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions,

- Amlodipine, which is used to treat high blood pressure,

- Ampicillin and sulbactam combination, used to treat bacterial infections,

- Atazanavir, an antiretroviral medication used to treat HIV/AIDS,

- Atenolol used to treat high blood pressure and heart-associated chest pain,

- Lamivudine which is used to prevent and treat HIV/AIDS. It is also used to treat chronic hepatitis B when other options are not possible. It is effective against both HIV-1 and HIV-2.

- Amitriptyline is used to treat depression symptoms, the H1N1 influenza vaccine has been rendered ineffective, and lipase-protease-amylase digestive enzymes are used to aid in the breakdown and digestion of fats, starches, and proteins in food.

- Antibiotics like isoniazid used for the treatment of tuberculosis,

- Carbamazepine to control certain types of seizures in people with epilepsy,

- Azithromycin used to treat certain bacterial infections, such as bronchitis, pneumonia, sexually transmitted diseases (STD), and infections of the ears, lungs, sinuses, skin, throat, and reproductive organs and artesunate injection used to treat severe malaria is also in the list.

Saudi Arabia had a market size of $7.8 billion in 2021 for pharmaceuticals which includes patented drugs of about $4.13 billion, generics at $2.87 billion and over-the-counter (OTC) drugs of $780 million.

The letter and the list of drugs specified in it state, “Saudi Food and Drug Authority (SFDA), Kingdom of Saudi Arabia, is inviting Indian drug and pharmaceutical manufacturers to participate in achieving drug security in the Kingdom of Saudi Arabia.”

There are a number of pharmaceutical products that are not present in the Kingdom despite the local market’s requirement for them.

The authority has prepared the list and prepared a package of incentives and facilities, and they are pleased to invite the Indian drug manufacturers to apply for the registration of the drugs mentioned in the attached list according to the mechanism mentioned in the list,” said IDMA secretary general Daara Patel.

Registration for sale of Medical Devices: Procedure and conditions

NPPA fixes Retail Price of 10 formulations: December 2022

Drug recall: This Blood Pressure tablets recalled

Kerala to cancel licences of Medical Stores selling antibiotics without prescription

NPPA fixes Retail Price of 12 scheduled formulations: December 2022

NPPA revises Retail Price of 107 scheduled formulations: December 2022

NABL asks Testing Laboratories to get product based accreditation

DCOIWA: Workshop on Medical Device Regulation and Legal Documentation organized

Bulk transfer of Blood and Blood Components: Procedure and Conditions

Latest Notifications regarding Pharmaceuticals
https://thehealthmaster.com/2022/12/24/300-life-saving-drugs-needed-from-indian-pharma-cos-saudi-arab/